Awakn Life Sciences chief scientific officer Professor David Nutt speaks with Proactive's Stephen Gunnion about the company's new commercial collaboration with Graft Polymer (UK) PLC (LSE:GPL). This partnership aims to advance Awakn's novel aminoindane new chemical entity (NCE) series, targeting trauma disorders such as PTSD, depression, and addictions.
In the interview, Nutt highlighted the serious nature of PTSD, describing it as a "disorder of this century." He noted that current treatments are inadequate, and the collaboration seeks to enhance the bioavailability and pharmacokinetics of these new therapeutics. The partnership also includes a £300,000 investment from Graft Polymer UK to improve drug delivery systems.
Nutt explained that the new technology could make treatment more efficient, reducing the time needed for therapeutic sessions, and improving patient outcomes. He emphasised the importance of finding better solutions for trauma-related disorders, particularly given the increasing prevalence of PTSD among populations affected by war and other traumatic events.